Kotecha Kalpu N, Kotecha B K, Shukla Vinay J, Prajapati Pradipkumar, Ravishankar B
Lecturer and Head, Department of Pharmacology, Institute of Ayurvedic Pharmaceutical Sciences, Gujarat Ayurved University, Jamnagar, Gujarat, India.
Drug Discovery Team, Research and Development, The Himalaya Drug Company, Makali, Bangalore, India.
Ayu. 2013 Jul;34(3):327-30. doi: 10.4103/0974-8520.123138.
Vasaguduchyadi Kwatha is a compound Ayurvedic formulation, indicated for the treatment of liver diseases, especially for Kamala (jaundice) and Panduroga (anemia). However, till date, no safety profile of this formulation has been reported; hence, in the present study, freshly prepared and market samples of Vasaguduchyadi Kwatha were evaluated for acute toxicity. Acute toxicity test was evaluated as per OECD 425 guidelines with 5 000 mg/kg as limit test in Wistar strain albino rats. Test formulations were administered to overnight fasted animals and parameters like body weight, behavioral changes, and mortality were assessed for 14 days. Hematological and biochemical parameters were assessed on 14(th) day. Results showed no significant changes in terms of behavioral changes, mortality, and body weight. Both the samples did not affect any of the hematological parameters. However, increase in blood urea level was observed. This study shows that both the samples of Vasaguduchyadi Kwatha are relatively safe up to the dose of 5 g/kg. However, further chronic toxicity evaluation is necessary to establish its safety profile on chronic administration.
Vasaguduchyadi Kwatha是一种复方阿育吠陀制剂,用于治疗肝脏疾病,尤其适用于卡马拉(黄疸)和潘杜罗加(贫血)。然而,迄今为止,尚未有该制剂安全性方面的报道;因此,在本研究中,对新制备的和市售的Vasaguduchyadi Kwatha样品进行了急性毒性评估。按照经合组织425指南,以5000毫克/千克作为Wistar品系白化大鼠的限量试验,对急性毒性试验进行了评估。将受试制剂给予过夜禁食的动物,并在14天内评估体重、行为变化和死亡率等参数。在第14天评估血液学和生化参数。结果显示,在行为变化、死亡率和体重方面没有显著变化。两个样品均未影响任何血液学参数。然而,观察到血尿素水平升高。本研究表明,Vasaguduchyadi Kwatha的两个样品在高达5克/千克的剂量下相对安全。然而,需要进一步进行慢性毒性评估,以确定其长期给药时的安全性。